Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET

Company Participants

James Carbonara - Hayden IR

Jennifer Simpson - Chief Executive Officer

Sue Horvath - Chief Financial Officer

Conference Call Participants

Jonathan Aschoff - ROTH MKM

Operator

Good day, everyone. And welcome to the Panbela Therapeutics Fourth Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions-and-comments after the presentation.

It is now my pleasure to turn the floor over to your host, James Carbonara. Sir, the floor is yours.

James Carbonara

Thank you. And once, again, welcome to Panbela’s fourth quarter 2022 earnings call. With me on the call are Jennifer Simpson, Chief Executive Officer; and Sue Horvath, Chief Financial Officer.

Before I turn the call over to Dr. Simpson, please note that statements made on this call that are not historical facts may be forward-looking statements. Significant risks and uncertainties that could cause actual results to differ from those expressed or implied in the forward-looking statements are detailed in the company’s annual report on Form 10-K and supplemented by the subsequently filed quarterly reports on Form 10-Q, as well as in other reports that the company files from time to time with the SEC.

Any forward-looking statements made on this call are made only as of today’s date and the company does not undertake any obligation to update or supplement any such statements to reflect subsequent developments.

Now I would like to turn the call over to Jennifer Simpson, CEO of Panbela. Jennifer, please proceed.

Jennifer Simpson

Thank you and thank you everyone for joining. I will begin the call with a review of our clinical development program, recent accomplishments and our upcoming milestones. Sue will then review the financial results and we will open it up for Q&A.

Starting with our Phase III program, in November, we enrolled our first patient in Europe for our ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. As a reminder, ASPIRE is a global randomized, double-blind, placebo-controlled clinical trial to evaluate ivospemin or SBP-101 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

We are really excited after just recently receiving regulatory approval for the opening of trial sites in Europe to have had our first patients enrolled in Italy. Having European enrollment underway is highly encouraging as we continue to ramp up the trial.